← Back to Search

Psychological Intervention for Misophonia

N/A
Waitlist Available
Led By Michael Twohig, PhD
Research Sponsored by Utah State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9-12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will study if combining traditional behavioral methods with a psychotherapy called Acceptance and Commitment Therapy (ACT) is a feasible and effective treatment for misophonia.

Who is the study for?
This trial is for adults who score at least five on the Misophonia Questionnaire, are stable on psychotropic medication for a month, speak English, and seek treatment for misophonia. It excludes those with psychological/neurological issues that overshadow their misophonia or require urgent care like psychosis or active self-harm.
What is being tested?
The study tests Acceptance and Commitment Therapy (ACT) combined with traditional behavioral intervention against progressive relaxation training plus psychoeducation in treating misophonia. Participants will be randomly assigned to one of these two approaches over 12 sessions.
What are the potential side effects?
As this trial involves psychological interventions rather than medications, typical side effects associated with drugs may not apply. However, participants might experience emotional discomfort as they engage in therapy and confront difficult feelings.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9-12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 9-12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Misophonia Questionnaire

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Acceptance and commitment therapyExperimental Treatment1 Intervention
ACT teaches skills to develop acceptance, mindfulness, and defusion from difficult internal experiences while increasing connections with personal values and encouraging meaningful behavioral changes. ACT for misophonia combines core ACT processes with a traditional audiological behavioral intervention for a integrated, multi-disciplinary approach for the assessment and treatment of misophonia. Treatment begins with a brief focus on the behavioral intervention, followed by the teaching of ACT skills to support the use of the behavioral methods. The intervention consists of 12 total individual sessions of ACT+behavioral management.
Group II: Progressive relaxation trainingActive Control1 Intervention
PRT for misophonia consists of basic psychoeducation for misophonia followed by PRT. PRT involves learning to tense and relax muscles. Early sessions focus on tensing and relaxing smaller muscle groups, while later sessions focus on larger muscle groups. Final sessions focus on relaxation as produced by recalling previous relaxation and a review of skills learned. PRT consists of 12 individual total sessions.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acceptance and commitment therapy
2019
N/A
~60

Find a Location

Who is running the clinical trial?

Utah State UniversityLead Sponsor
45 Previous Clinical Trials
4,698 Total Patients Enrolled
Michael Twohig, PhDPrincipal InvestigatorUtah State University
1 Previous Clinical Trials
21 Total Patients Enrolled

Media Library

Acceptance and commitment therapy Clinical Trial Eligibility Overview. Trial Name: NCT05601284 — N/A
Misophonia Research Study Groups: Acceptance and commitment therapy, Progressive relaxation training
Misophonia Clinical Trial 2023: Acceptance and commitment therapy Highlights & Side Effects. Trial Name: NCT05601284 — N/A
Acceptance and commitment therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT05601284 — N/A
~18 spots leftby Oct 2025